SC
OBIO icon

Sculptor Capital’s Orchestra BioMed OBIO Stock Holding History

Sculptor Capital’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-542,847
Closed -$5.41M – 1121
2022
Q2 		$5.41M Buy
542,847
+51,649
+11% +$513K 0.06% 394
2022
Q1 		$4.87M Buy
+491,198
New +$4.85M 0.04% 453

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Sculptor Capital's OBIO Position: Q3 2022 in Review

Sculptor Capital sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 542,847 shares — an estimated $5.41M sold.

Sculptor Capital first reported a position in OBIO in Q1 2022 and held it in 2 quarters. The position peaked at $5.41M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Sculptor Capital reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Sculptor Capital sold 542,847 Orchestra BioMed shares in Q3 2022, an estimated $5.41M.
  • Sculptor Capital first reported a position in Orchestra BioMed in Q1 2022 and held it in 2 quarters.
  • Sculptor Capital's Orchestra BioMed position peaked at $5.41M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Sculptor Capital's 13F filing for Q3 2022, filed 14 Nov 2022.